npj Vaccines (Oct 2024)

Toxoplasma WH3 Δrop18 acts as a live attenuated vaccine against acute and chronic toxoplasmosis

  • Cong Wang,
  • Shengnan Fu,
  • Xin Yu,
  • Hang Zhou,
  • Famin Zhang,
  • Lingling Song,
  • Ji Zhao,
  • Yun Yang,
  • Jianbing Du,
  • Qingli Luo,
  • Jilong Shen,
  • Li Yu

DOI
https://doi.org/10.1038/s41541-024-00996-9
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Toxoplasma gondii is a significant zoonotic pathogen of toxoplasmosis in humans and animals. Here a live attenuated Toxoplasma vaccine of WH3 Δrop18 was developed. The results showed that all mice vaccinated with WH3 Δrop18 were able to survive when challenge with various strains of Toxoplasma, including RH (type I), ME49 (type II), WH3 or WH6 (type Chinese 1). No cysts, if few, in the brain of the vaccinated animals were seen after challenge with cyst forming strains of ME49 or WH6. Vaccination with the WH3 Δrop18 triggered a strong immune response, including significantly increased level of the cytokines (IFN-γ, IL-12, TNF-α and IL-10) and the activation of CD4+ and CD8+ T-lymphocytes and long term of specific antibodies against Toxoplasma. Our results strongly indicate that vaccine of WH3 Δrop18 might provide effective immune protection against a wide range strains of Toxoplasma infections and be a promising live attenuated vaccine candidate.